Newsroom | 48829 results

PECHINO, SHANGHAI e HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), azienda biotech globale impegnata nel progresso della scoperta farmacologica innovativa, oggi ha annunciato la riuscita quotazione allo STAR Market della Borsa di Shanghai. L'operazione fa seguito alla quotazione dell'azienda alla Borsa di Hong Kong, avvenuta nel mese di settembre del 2022, e costituisce una pietra miliare nella trasformazione di Biocytogen ne...

BEIJING & SHANGHAI & HONGKONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen”, SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine erfolgreiche Notierung an der Shanghai Stock Exchange STAR Market bekannt. Dies folgt auf die Notierung des Unternehmens an der Hong Kong Stock Exchange im September 2022 und markiert einen bedeutenden Meilenstein bei der Etablierung von Biocytogen als ers...

PEKÍN, SHANGHÁI Y HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. («Biocytogen», SSE: 688796; HKEX: 02315), empresa biotecnológica global dedicada a la investigación para crear fármacos innovadores, acaba de anunciar su salida a bolsa en el mercado STAR de la Bolsa de Shanghái. Esto se produce tras empezar a cotizar en la Bolsa de Hong Kong en septiembre de 2022 y supone un importante hito para Biocytogen como la primera empresa farmacéutica innovadora global con dobl...

PÉKIN, SHANGHAI et HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (« Biocytogen », SSE : 688796 ; HKEX : 02315), une société internationale de biotechnologie spécialisée dans la découverte de médicaments innovants, a annoncé aujourd’hui son introduction réussie sur le marché STAR de la Bourse de Shanghai. Ce lancement fait suite à celui de la société à la Bourse de Hong Kong en septembre 2022 et marque une étape importante dans l’établissement de Biocytogen en tant q...

BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), een wereldwijd biotechnologiebedrijf dat actief is op het gebied van innovatieve geneesmiddelenontwikkeling, heeft vandaag bekendgemaakt dat het met succes is genoteerd aan de STAR Market van de Shanghai Stock Exchange. Dit volgt op de notering van het bedrijf aan de Hong Kong Stock Exchange in september 2022 en markeert een belangrijke mijlpaal in de positio...

BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcin...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Safety Assessment Global Market Report 2025" has been added to ResearchAndMarkets.com's offering. The pharmaceutical safety assessment market has demonstrated significant growth, expanding from $10.47 billion in 2024 to an anticipated $11.32 billion in 2025, reflecting a CAGR of 8.1%. This growth stems from heightened demand for preclinical research, stricter drug safety regulations, increased outsourcing to contract research organizations, advances...

SAN FRANCISCO--(BUSINESS WIRE)--Lumos Labs, announced today that the FDA has granted 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD....

BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced elluminate AI agents – intelligence in action across the entire elluminate ecosystem. First previewed at the company’s ENGAGE conference in October, the AI agents are embedded within four key pillars of the elluminate Clinical Data Cloud®: Data Mapping, Data Review, RBQM, and Study Operations. With governed data, explainable intelligence, and human supervision, the comp...

LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company. The funding will enable the delivery of first-in-human Phase 1/2a clinical trials to...